roche registration ltd. - daclizumab - graft rejection; kidney transplantation - immunosuppressants - zenapax is indicated for the prophylaxis of acute organ rejection in de novo allogenic renal transplantation and is to be used concomitantly with an immunosuppressive regimen, including cyclosporine and corticosteroids in patients who are not highly immunised.
European Union -
English -
EMA (European Medicines Agency)